Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.
−Removed: Unregistered Sales of Equity Securities for the Three Months Ended March 31, 2024
−Removed: There were no unregistered sales of equity securities during the three months ended March 31, 2024.
+Added: Unregistered Sales of Equity Securities for the Three Months Ended June 30, 2024
+Added: There were no unregistered sales of equity securities during the three months ended June 30, 2024.
Use of Proceeds from our IPO
The net proceeds from our IPO, after deducting underwriting discounts and commissions and offering expenses of $28.6 million, were $321.0 million.
−Removed: We are holding a significant portion of the balance of the net proceeds from our IPO in money market mutual funds, U.S.
+Added: We are holding a significant portion of the remaining balance of the net proceeds from our IPO in money market mutual funds, U.S.
Treasury bills, corporate debt securities, and U.S.
1 unchanged sentence
There has been no material change in our planned use of the net proceeds from our IPO described in the final prospectus for our IPO filed on July 23, 2021 with the SEC pursuant to Rule 424(b)(4) of the Securities Act.
+Added: 3.1 Amended and Restated Certificate of Incorporation of Caribou Biosciences, Inc.
+Added: (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No.
+Added: 001-40631) filed by the Registrant with the SEC on July 28, 2021)
+Added: 3.2 Amended and Restated Bylaws of Caribou Biosciences, Inc.
+Added: (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K (File No.
+Added: 001-40631) filed by the Registrant with the SEC on July 28, 2021)
+Added: 4.1 Description of Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (File No.
+Added: 001-40631), filed with the SEC on March 21, 2022)
+Added: Amendment to the Officer Employment Agreement , dated July 27, 2021 , by and between the Registrant and Steven B.
+Added: Kanner, Ph.D.
+Added: 31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: 31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: 32.1** Certification of Principal Executive Officer Pursuant to 18 U.S.C.
+Added: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: 32.2** Certification of Principal Financial Officer Pursuant to 18 U.S.C.
+Added: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: 101.INS* Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
+Added: 101.SCH* Inline XBRL Taxonomy Extension Schema Document
+Added: 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document
+Added: 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document
+Added: 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document
+Added: 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document
+Added: 104* Cover Page Interactive Data File (embedded within the Inline XBRL document)
+Added: ______________________________________________
+Added: * Filed herewith.
+Added: ** Furnished herewith.
+Added: + Indicates management contract or compensatory plan
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: Caribou Biosciences, Inc.
+Added: August 6, 2024
+Added: /s/ Rachel E.
+Added: President and Chief Executive Officer
+Added: (Principal Executive Officer)
+Added: August 6, 2024
+Added: Chief Financial Officer
+Added: (Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.